Depression Clinical Trial Landscape

The depression clinical trial landscape in 2026

Major depressive disorder is undergoing its most significant therapeutic renewal since the introduction of SSRIs in the late 1980s. The approval of esketamine (Spravato, Janssen) for TRD in 2019 and zuranolone (Zurzuvae, Sage/Biogen) for MDD and PPD in 2023 validated two entirely new mechanisms — NMDA receptor antagonism and positive allosteric modulation of GABA-A receptors — and opened a decade of follow-on development. As of 2026, the MDD pipeline includes ketamine analogs, psilocybin-based therapies, AMPA potentiators, and kappa-opioid receptor antagonists alongside the established monoamine targets.

The active trials in our database reflect this mechanistic breadth. COMPASS Pathways and Usona Institute are running Phase 2/3 psilocybin trials; Lykos Therapeutics (formerly MAPS PBC) continues MDMA-assisted therapy research despite regulatory setbacks. Axsome Therapeutics has AXS-05 (dextromethorphan/bupropion) approved as Auvelity and is pursuing TRD and Alzheimer's agitation indications. Neumora Therapeutics is advancing navacaprant, a kappa-opioid receptor antagonist, in Phase 3. The pipeline is broad, mechanistically diverse, and moving quickly.

Treatment-resistant depression — defined as failure of two or more adequate antidepressant trials — represents roughly 30% of MDD patients and is the most commercially valuable sub-population. Trials specifically targeting TRD are a high-priority signal for CNS BD and investment teams. DataLookout lets you filter for TRD-specific trial registrations so they never get missed.

• NMDA receptor antagonists — esketamine (approved), ketamine, zuranolone follow-ons, PCN-101 (R-ketamine, ProCessa)
• Psilocybin and serotonergic psychedelics — COMP360 (COMPASS Pathways), psilocybin (Usona), LSD analogs
• Neuroactive steroids / GABA-A modulators — zuranolone (approved), next-gen TSPO ligands
• Kappa-opioid receptor antagonists — navacaprant (Neumora), BTRX-335140 (BlackThorn)
• AMPA potentiators and glutamate modulators — riluzole, amantadine combinations
• Neuromodulation — TMS, tDCS, DBS for TRD; closed-loop stimulation protocols

What we monitor for depression

Our system pulls from the ClinicalTrials.gov API every day. For a depression watch profile, you can configure a saved search for:

• Keywords: "major depressive disorder," "MDD," "treatment-resistant depression," "TRD," "postpartum depression," "PPD," "bipolar depression," "esketamine," "psilocybin," "zuranolone," "ketamine," "NMDA"
• Phase filters: Phase 1 (novel mechanisms/first-in-human), Phase 2 (proof-of-concept), Phase 3 (pivotal/registration trials)
• Sponsor type: large pharma (Janssen, AbbVie, Pfizer), specialist CNS biotech, NIH/NIMH-funded academic
• Study status: not yet recruiting, recruiting, active not recruiting (completed enrollment)
• Sub-indication: filter for TRD-specific protocols vs. broad MDD vs. postpartum depression specifically

Psychedelic-assisted therapy — regulatory uncertainty, sustained clinical activity

Psychedelic-assisted therapies represent one of the most scientifically contested and commercially watched segments in all of CNS drug development. The FDA issued a Complete Response Letter to Lykos Therapeutics for MDMA-assisted therapy for PTSD in 2024, citing concerns about functional unblinding and trial design — a setback that cast a shadow over the broader field. However, psilocybin-based development has continued. COMPASS Pathways reported Phase 2b data for COMP360 showing dose-dependent response in TRD, and Usona Institute is running a Phase 3 trial under a Special Protocol Assessment.

For CNS BD teams and investors, the psychedelic pipeline requires careful monitoring of both clinical registrations and regulatory guidance documents. New Phase 1 or Phase 2 registrations from well-capitalized programs remain high-signal events — particularly those with novel delivery formats (oral vs. intravenous) or synthetic analogs with reduced hallucinogenic burden. DataLookout surfaces those registrations the day they appear.

Patient advocacy groups focused on mental health — including those representing TRD and suicide-risk populations — are also active watchers of this pipeline. Access to innovative therapies and the design of compassionate use programs are critical issues for these organizations.

Who uses depression trial monitoring

• CNS pharma and biotech BD teams — tracking new mechanisms, Phase 2 transitions, and Phase 3 initiations across NMDA antagonists, neuroactive steroids, psychedelics, and novel monoamine targets
• Mental health and neuroscience investors — monitoring Phase 2/3 data catalysts and new trial registrations from companies that are likely licensing or acquisition targets
• CNS-focused CROs — identifying new sponsor relationships and site opportunities in complex, protocol-intensive TRD and psychedelic trials
• Patient advocacy organizations — tracking access to novel therapies, compassionate use programs, and the inclusion of hard-to-treat populations in Phase 3 designs
• Academic psychiatry research groups and KOLs — monitoring industry programs that may seek investigator sites or publication collaborations

Phase 3 depression trial pipeline (2025–2026)

The 2026 MDD/TRD Phase 3 landscape is the most mechanistically diverse in the history of the indication. Key programs currently in Phase 3 or recently completed:

Note: Phase 3 landscape evolves rapidly — new trials register and complete on a monthly basis. DataLookout surfaces new registrations the day they appear on ClinicalTrials.gov.

Kappa-opioid receptor antagonists: the 2026 mechanism race

The kappa-opioid receptor (KOR) has emerged as one of the most closely watched targets in CNS drug development. KOR agonism mediates dysphoria and anhedonia — the motivational deficit at the core of both depression and stress responses. KOR antagonists theoretically reverse this by reducing stress-induced dysphoria without the addiction liability of mu-opioid agonists.

Two programs are now in Phase 3 with different profiles. Neumora's navacaprant (partnered with AstraZeneca) is in the KOASTAL Phase 3 program specifically enriching for patients with high anhedonia scores. Janssen's aticaprant is also in Phase 3 in a similar anhedonia-enriched population. Both programs represent the first major clinical test of the KOR hypothesis at a registrational scale. The competitive read-out between them — likely in 2025–2026 — will either validate KOR antagonism as a new antidepressant class or close the hypothesis.

For CNS BD teams, the question is not just whether these drugs work, but which biomarker strategy for anhedonia proves most predictive — a design decision that will affect how Phase 3 depression trials are constructed for the next decade.

Related clinical trial monitors

• Anxiety clinical trials — overlapping GABAergic, serotonergic, and psychedelic programs; Xenon Pharmaceuticals and other CNS companies running comorbid programs
• Alzheimer's disease clinical trials — overlapping neuroinflammation programs and behavioral symptom management trials
• Parkinson's disease clinical trials — related neurodegeneration targets and CNS drug development infrastructure
• Multiple sclerosis clinical trials — shared CNS development platform companies and neuroimmunology
• ALS clinical trials — overlapping CNS neurology infrastructure and neuroprotection programs

Frequently asked questions